Tranxene (clorazepate) belongs to the class of drugs called benzodiazepines. It is an anxiolytic, which means it has properties that are useful in treating anxiety and panic-related conditions. It is also used in alcohol withdrawal. Apart from these uses, it is also prescribed as an additive in the management of convulsions and epilepsy.

How Does Tranxene Work?

This drug acts on gamma-aminobutyric acid (GABA) receptors found in various regions of the brain. These receptors are also known as benzodiazepine receptors. The action of Tranxene on GABA receptors increases the inhibitory action of the neurotransmitter in that region of the brain. This action on GABA receptors appears to produce the medication’s anxiolytic, sedative, and anticonvulsant actions.

Dosage FAQs

Possible Side Effects

This medication shares many of the same side effects of other benzodiazepines, including:

Drug Interactions

If you are prescribed this medication, ensure that you disclose all medications, vitamins, and supplements you take regularly to your doctor. The following drug interactions may occur with this treatment:

Additionally, the following drugs may affect the metabolism of Serax and/or increase the risk of toxicity if administered with Serax:

Safe Withdrawal from Tranxene

You should not stop taking this medication abruptly. In order to reduce the withdrawal symptoms, you should gradually taper down the dose. Consult your physician and develop a safe plan to reduce the medication in your system. Possible symptoms of withdrawal include:

Reference:

  1. Rickels R, Ryan M. Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry 2002; 63(suppl 14):9–16.
  2. Sramek JJ, Zarotsky V, Cutler NR. Generalised anxiety disorder. Drugs 2002; 62:1635–1648.
  3. Ballanger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry 2001; 62(suppl 11):53–58
  4. Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, AA.; Vennat, B.; Llorca, PM.; Eschalier, A. (November 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Annales Pharmaceutiques Francaises 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.

Page content reviewed by James Pendleton, ND.